Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA First-ever demonstration of substantial improvements in muscle health with exon skipping – statistically significant reduction in fibrosis driven by decreases in inflammation and necrosis, coupled with transition from regenerative to mature muscle; decreases in creatine kinase and circulating inflammatory biomarkers Dystrophin expression stabilized between 24 and 48 weeks and averaged 7.8%, with 88% o

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ongoing in 200 mg cohort of RestorAATion-2 clinical trial of WVE-006 in AATD with data expected in 2025; second single dose cohort initiated at 400 mg On track to deliver FORWARD-53 48-week data in DMD and feedback from regulators in 1Q 2025 IND submission expected 2H 2025 for potentially registrational WVE-003 Phase 2/3 study in HD with caudate atrophy as a primary endpoint Cash and cash equivalents of $302.1 million as of December 31, 2024, with runway expected into 2027 Investor conference call and webcast at 8:30 a.m. ET today

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, March 4, 2025, to review the company's fourth quarter and full year 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can j

WVE-007 is a novel, long-acting GalNAc-siRNA targeting INHBE mRNA – a genetically validated target that provides a new approach for healthy, sustainable weight loss (fat loss with muscle preservation) Proof-of-concept clinical data from INLIGHT are expected in 2025 CAMBRIDGE, Mass., Feb. 06, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced clinical trial application (CTA) approval and initiation of the Phase 1 INLIGHT clinical trial of WVE-007 in obesity. WVE-007 is a long-acting GalNAc-conjugated small interfering RNA (siRNA) that tar

Entering 2025 having demonstrated rapid translation of genetic insights to positive clinical data; advancing clinically validated and multi-modal pipeline with the potential to treat well over 100 million patients CTAs submitted for Phase 1 INLIGHT clinical trial of WVE-007, a novel, long-acting, muscle-sparing GalNAc-siRNA approach for obesity targeting INHBE grounded in human genetics; proof-of-concept clinical data expected in 2025 Pioneering entirely new therapeutic field of RNA editing and building on positive WVE-006 proof-of mechanism clinical data; expect multidose AATD data, new preclinical data from hepatic and extra-hepatic RNA editing programs and candidate selections in 2025

WVE-007 is a novel approach for treating obesity and is designed to silence INHBE to achieve healthy, sustainable weight loss through fat burning, muscle maintenance and the potential for once or twice-annual administration WVE-007 is Wave's first siRNA program to enter clinical development and uses best-in-class oligonucleotide chemistry and GalNAc delivery Wave expects to initiate the first-in-human study of WVE-007 in 1Q 2025 CAMBRIDGE, Mass., Dec. 23, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the submission of its first clin

CAMBRIDGE, Mass., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13, 2025, at 9:45 a.m. PT / 12:45 p.m. ET. A live webcast of this presentation can be accessed by visiting "Investor Events" on the Investor Relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this presentation w

CAMBRIDGE, Mass., Nov. 26, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in two upcoming investor conferences in December. 7ᵗʰ Annual Evercore HealthCONx ConferenceDate: Tuesday, December 3, 2024Analyst-led fireside chat: 3:00 p.m. ET Citi 2024 Global Healthcare Conference Date: Wednesday, December 4, 2024"Neuromuscular Disorders" panel: 1:00 p.m. ET Live webcasts of these presentations can be accessed by visiting "Investor Events" on

CAMBRIDGE, Mass., Nov. 15, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 20, 2024, at 4:30 p.m. GMT / 11:30 a.m. ET. A live webcast of this presentation can be accessed by visiting "Investor Events" on the Investor Relations section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. A replay of this

Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that offer first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s Received supportive initial feedback from FDA on WVE-003; FDA is engaged in discussing pathways to accelerated approval and open to Wave's plan to evaluate biomarkers, in

Jefferies initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $26.00

Raymond James upgraded Wave Life Sciences from Outperform to Strong Buy and set a new price target of $22.00

JP Morgan resumed coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $13.00 from $10.00 previously

B. Riley Securities initiated coverage of Wave Life Sciences with a rating of Buy and set a new price target of $11.00

JP Morgan initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $10.00

Wells Fargo initiated coverage of Wave Life Sciences with a rating of Overweight and set a new price target of $11.00

Leerink Partners upgraded Wave Life Sciences from Market Perform to Outperform and set a new price target of $12.00 from $5.00 previously

Raymond James initiated coverage of Wave Life Sciences with a rating of Outperform and set a new price target of $7.00

Jefferies downgraded Wave Life Sciences from Buy to Hold and set a new price target of $5.00 from $7.00 previously

SVB Leerink reiterated coverage of WAVE Life Sciences with a rating of Market Perform and set a new price target of $7.00 from $10.00 previously

4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

4/A - Wave Life Sciences Ltd. (0001631574) (Issuer)

4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

4 - Wave Life Sciences Ltd. (0001631574) (Issuer)

8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

144 - Wave Life Sciences Ltd. (0001631574) (Subject)

10-K - Wave Life Sciences Ltd. (0001631574) (Filer)

8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

SCHEDULE 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

S-8 - Wave Life Sciences Ltd. (0001631574) (Filer)

S-3ASR - Wave Life Sciences Ltd. (0001631574) (Filer)

8-K - Wave Life Sciences Ltd. (0001631574) (Filer)

CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced the appointment of Erik Ingelsson, MD, PhD, as Chief Scientific Officer. Dr. Ingelsson will drive Wave's emerging therapeutic portfolio strategy, including growing its genetics and genomics capabilities for identifying new, high impact targets, and leveraging the company's best-in-class multimodal discovery and development platform to advance transformative RNA medicines. Most recently, Dr. Ingelsson served as Senior Vice President, Head of Target Discovery, at GSK

BOTHELL, Wash., March 21, 2022 (GLOBE NEWSWIRE) -- Athira Pharma, Inc. (NASDAQ:ATHA), a late clinical-stage biopharmaceutical company focused on developing small molecules to restore neuronal health and slow neurodegeneration, today announced the appointment of Michael A. Panzara, M.D., MPH to its Board of Directors. Dr. Panzara currently serves as Chief Medical Officer, Head of Therapeutics Discovery and Development at Wave Life Sciences (NASDAQ:WVE) and brings over 20 years of biopharmaceutical industry experience developing therapies for neurological disorders, including in leadership roles at Sanofi Genzyme and Biogen. "Mike is a recognized and experienced leader in the development

CAMBRIDGE, Mass., Dec. 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, announced today that Jonathan Rosin has been appointed as Chief Human Resources Officer (CHRO). As CHRO, Mr. Rosin will provide strategic enterprise counsel and leadership, both as a member of Wave’s Executive Team and by leading the human resources function. “Jonathan is an accomplished leader with the breadth of human resources experience necessary to help guide Wave as we prepare to support five programs in clinical trials in 2021, as well as advance a robust precl

Statistically significant and clinically meaningful improvement of 3.8 seconds in Time-to-Rise vs. natural history with largest effect observed relative to any approved dystrophin restoration therapy at 48 weeks; additional functional benefits observed in other outcome measures including NSAA First-ever demonstration of substantial improvements in muscle health with exon skipping – statistically significant reduction in fibrosis driven by decreases in inflammation and necrosis, coupled with transition from regenerative to mature muscle; decreases in creatine kinase and circulating inflammatory biomarkers Dystrophin expression stabilized between 24 and 48 weeks and averaged 7.8%, with 88% o

Dosing underway in INLIGHT trial of WVE-007 in obesity with clinical data expected in 2H 2025; enrollment complete in first single dose cohort Multi-dosing ongoing in 200 mg cohort of RestorAATion-2 clinical trial of WVE-006 in AATD with data expected in 2025; second single dose cohort initiated at 400 mg On track to deliver FORWARD-53 48-week data in DMD and feedback from regulators in 1Q 2025 IND submission expected 2H 2025 for potentially registrational WVE-003 Phase 2/3 study in HD with caudate atrophy as a primary endpoint Cash and cash equivalents of $302.1 million as of December 31, 2024, with runway expected into 2027 Investor conference call and webcast at 8:30 a.m. ET today

CAMBRIDGE, Mass., Feb. 25, 2025 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, March 4, 2025, to review the company's fourth quarter and full year 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can j

Achieved first-ever RNA editing in humans in RestorAATion-2 trial of WVE-006 (GalNAc-AIMer) in alpha-1 antitrypsin deficiency and announced three wholly owned GalNAc-AIMer preclinical programs that offer first-in-class approaches to address unmet needs in cardiometabolic diseases WVE-007 (INHBE GalNAc-siRNA) clinical trial on track for 1Q 2025; preclinical data demonstrates opportunities for monotherapy, for synergistic use with GLP-1s, and for maintenance to avoid rebound weight gain following cessation of GLP-1s Received supportive initial feedback from FDA on WVE-003; FDA is engaged in discussing pathways to accelerated approval and open to Wave's plan to evaluate biomarkers, in

CAMBRIDGE, Mass., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Tuesday, November 12, 2024, to review the company's third quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: https://ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference

Mean muscle content-adjusted dystrophin expression of 9.0% and unadjusted dystrophin of 5.5%, with high consistency across participants, in a prespecified analysis; dystrophin was comprised of two isoforms consistent with Becker muscular dystrophy patients who display milder disease Data demonstrated meaningful improvement in serum biomarkers for muscle health, with localization of WVE-N531 in myogenic stem cells and regeneration of myofibers Skeletal muscle concentrations of ~41,000 ng/g combined with 61-day tissue half-life support monthly dosing going forward; preclinical data suggest participants may have even higher concentrations in heart and diaphragm WVE-N531 was safe and well tol

Successful clinical translation of Wave's RNA medicines platform in HD patients with WVE-003 provides further validation of Wave's proprietary platform with PN and stereochemistry; opt-in package for WVE-003 submitted to partner Takeda and engagement with regulators initiated to discuss potential path to accelerated approval Dystrophin data on track for 3Q 2024 from potentially registrational FORWARD-53 trial of WVE-N531, which has previously demonstrated industry-leading exon skipping of 53%; positive data would unlock a best-in-class functional dystrophin franchise for DMD Dosing initiated in 3Q 2024 in RestorAATion-2 clinical trial of WVE-006 in AATD patients; proof-of-mechanism da

CAMBRIDGE, Mass., Aug. 01, 2024 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (NASDAQ:WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, will host a live webcast and conference call at 8:30 a.m. ET on Thursday, August 8, 2024, to review the company's second quarter 2024 financial results and provide business updates. The webcast and conference call may be accessed by visiting "Investor Events" on the investors section of the Wave Life Sciences website: ir.wavelifesciences.com/events-publications/events. Analysts planning to participate during the Q&A portion of the live call can join the conference call at the f

Statistically significant, potent, and durable allele-selective silencing: 46% mean reduction in CSF mutant huntingtin (mHTT) protein compared to placebo, preservation of wild-type huntingtin (wtHTT) protein, and generally safe and well-tolerated profile achieved in 30 mg multidose cohort Statistically significant correlation between mHTT lowering and slowing of caudate atrophy - an imaging biomarker predictive of clinical outcomes Wave to engage regulators on a clinical development path for WVE-003 that would support a potential accelerated approval, and will submit its opt-in package to program partner Takeda Data provide further validation for Wave's RNA medicines pla

RestorAATion-2 clinical trial of WVE-006 in AATD patients underway; expected proof-of-mechanism data in patients with AATD remains on track for 2024 INHBE program for obesity expected clinical trial initiation in 1Q 2025; preclinical data demonstrate weight loss similar to semaglutide, fat loss with no loss of muscle mass, and curtailed rebound weight gain upon cessation of semaglutide, with potential for dosing 1 – 2 times per year Continued momentum in GSK collaboration; advancing first two GSK collaboration programs following successful target validation; both programs utilize Wave's GalNAc-siRNA format and discovery collaboration continues to span all Wave modalitie

SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

SC 13D/A - Wave Life Sciences Ltd. (0001631574) (Subject)

SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)

SC 13G/A - Wave Life Sciences Ltd. (0001631574) (Subject)